Corvus Pharmaceuticals, Inc. (CRVS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Corvus Pharmaceuticals, Inc._July 21, 2026 0001626971 false 0001626971 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (
How this was made
The 30-second read
Why it matters
This is a governance event with a specific effective date, but the disclosure does not state strategic, financial, or regulatory causes.
Market read
The market may react modestly to board composition changes, but there is no new business or financial catalyst in the text.
What to watch
Traders may want to watch for subsequent filings that name a replacement director, committee changes, or any linked executive/officer appointments not included in this brief 8-K.
Background
The filing is an SEC Form 8-K under Item 5.02, covering director departure and related board/officer changes.
Ticker impact
Corvus Pharmaceuticals disclosed that director Ian T. Clark will resign from its board effective July 22, 2026.
Likely limited near-term impact unless follow-on disclosures name a replacement or cite strategic reasons.
The 8-K is a primary-source governance update (Item 5.02) with a stated effective date, but it does not include new guidance, financial results, or transaction terms.
Market effects
Minimal, as this is company-specific governance news with no sector-wide regulatory or clinical read-across.
Minimal, US-listed biotech governance update.
Minimal, no cross-border transaction or regulatory action described.
Counterpoint
The resignation may be routine (end of term, personal reasons) and could have little bearing on the company’s pipeline or financing plans.
Key entities
- issuerCorvus Pharmaceuticals, Inc.
Nasdaq-listed company filing the 8-K; disclosed director resignation effective July 22, 2026.
- directorIan T. Clark
Board member who delivered notice of resignation effective July 22, 2026.
- officerLeiv Lea
Chief Financial Officer signing the 8-K.
